Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dates: 2008 - 2022
Funding: Bayer Schering Pharma
Collaborators: Diabetes Trial Unit (DTU), University of Oxford; University of Beijing
Information: Alastair Gray

The ACE trial is being conducted in Hong Kong and China, and is investigating the effects of an oral anti-diabetes drug containing acarbose on preventing recurrent cardiovascular disease (CVD) and type 2 diabetes in individuals with CVD and pre-diabetes. The trial is recruiting approximately 7,500 individuals with CVD, who also have pre-diabetes. Trial results are expected in 2013.

HERC is conducting the economic analysis alongside the trial.